IPO Year: 2023
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/14/2024 | $18.00 → $6.00 | Buy → Neutral | H.C. Wainwright |
| 7/8/2024 | $13.00 | Equal Weight → Overweight | Wells Fargo |
| 12/13/2023 | $11.00 | Equal Weight | Wells Fargo |
| 12/8/2023 | $8.00 | Neutral | Citigroup |
| 9/13/2023 | $19.00 | Overweight → Equal-Weight | Morgan Stanley |
| 9/5/2023 | $44.00 | Buy | H.C. Wainwright |
| 5/30/2023 | Overweight | Morgan Stanley | |
| 5/30/2023 | $31.00 | Buy | Jefferies |
| 5/30/2023 | $68.00 | Overweight | Piper Sandler |
| 5/30/2023 | Outperform | TD Cowen |
SC 13G - ACELYRIN, Inc. (0001962918) (Subject)
SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)
SC 13G - ACELYRIN, Inc. (0001962918) (Subject)
SC 13G - ACELYRIN, Inc. (0001962918) (Subject)
SC 13G - ACELYRIN, Inc. (0001962918) (Subject)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 program in first quarter of 2025 LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the formation of a scientific and patient advisory board comprised of leading experts and advocates in thyroid eye disease (TED). This group of advisors will provide important strategic input, clinical expertise and patient perspectives as ACELYRIN prepares t
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive results from the company's global Phase 3 clinical trial of izokibep in moderate-to-severe hidradenitis suppurativa (HS) patients will be shared as a late-breaking oral presentation at the 2024 European Academy of Dermatology and Venereology taking place September 25-28, 2024 in Amsterdam, Netherlands. Presentation details are as follows: Title:Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Moderate-to-Severe Hidradenitis Suppurativ
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive data from its Phase 1/2 clinical trial of lonigutamab (an anti-insulin-like growth factor 1 receptor, or IGF-1R) in thyroid eye disease (TED) will be shared in a rapid-fire oral presentation at the 42nd Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS) taking place from September 12-14, 2024 in Rotterdam, Netherland
LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that members of its management team will participate in fireside chats and 1x1 meetings at the following investor conferences: Wells Fargo Healthcare Conference 2024Date: Thursday, September 5, 2024Location: Boston, MAFireside chat: 1:30 PM - 2:05 PM ET Morgan Stanley 22nd Annual Global Healthcare Conference Date: Friday, September 6, 2024Location: New York, NYFireside chat: 11:30 AM - 12:05 PM ET H.C. Wainwright 26th Annual Global Investment Confere
Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint of HiSCR75 at 12 weeks Company to prioritize development of lonigutamab; dose confirmation ongoing in Phase 2 trial with plans to initiate Phase 3 program in Q1 2025 Cash, cash equivalents, and short-term marketable securities at June 30, 2024 of $635.2 million; projected to extend cash runway to mid-2027 Company to hold webcast and conference call at 5:00pm ET today LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that the Phase 3 tria
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, August 13, 2024 at 5:00 p.m. ET to discuss its second quarter 2024 financial results and provide a corporate update. A live webcast of the conference call will be available on the Company's website under Events & Presentations. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRIN, INC.ACELYRIN, INC. (NASDAQ:SLRN) is a Los Angeles area-based late-stage clinical biopharma company –
LOS ANGELES, June 05, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive results from the company's global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) will be shared as a late breaking oral presentation at the 2024 European Alliance of Associations for Rheumatology Congress taking place June 12-15 in Vienna, Austria. Izokibep is a small protein therapeutic designed to inhibit IL-17A, a validated mechanism for the treatment of PsA and other immune-mediated diseases. Presentation details are as follow
Lonigutamab is the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease (TED) patients LOS ANGELES, May 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED) will be shared as a late breaking oral presentation at the Endocrine Society's Annual Meeting (ENDO 2024), taking place from June 1-4 in Boston, MA. Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targ
Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by end of third and fourth quarter of 2024, respectively Reported positive proof-of-concept for lonigutamab in thyroid eye disease patients and positive top-line Phase 2b/3 data for izokibep in psoriatic arthritis Cash, cash equivalents, and short-term marketable securities at March 31, 2024 of $678.5 million Company also announced changes to leadership team LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerat
Mina Kim appointed Chief Executive Officer and to Board of Directors ACELYRIN Founder Shao-Lee Lin, M.D., Ph.D., steps down as Chief Executive Officer Shephard (Shep) Mpofu, M.D., MRCP, FRCP named Chief Medical Officer, Gil Labrucherie, the company's Chief Financial Officer, additionally named Chief Business Officer, and Sanam Pangali named Chief Legal Officer and Head of People LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that ACELYRIN's founder Shao-Lee Lin, M.D., Ph.D. has stepped down as Chief Ex
H.C. Wainwright downgraded ACELYRIN from Buy to Neutral and set a new price target of $6.00 from $18.00 previously
Wells Fargo upgraded ACELYRIN from Equal Weight to Overweight and set a new price target of $13.00
Wells Fargo initiated coverage of ACELYRIN with a rating of Equal Weight and set a new price target of $11.00
Citigroup initiated coverage of ACELYRIN with a rating of Neutral and set a new price target of $8.00
Morgan Stanley downgraded ACELYRIN from Overweight to Equal-Weight and set a new price target of $19.00
H.C. Wainwright initiated coverage of ACELYRIN with a rating of Buy and set a new price target of $44.00
Morgan Stanley initiated coverage of ACELYRIN with a rating of Overweight
Jefferies initiated coverage of ACELYRIN with a rating of Buy and set a new price target of $31.00
Piper Sandler initiated coverage of ACELYRIN with a rating of Overweight and set a new price target of $68.00
TD Cowen initiated coverage of ACELYRIN with a rating of Outperform
10-Q - ACELYRIN, Inc. (0001962918) (Filer)
8-K - ACELYRIN, Inc. (0001962918) (Filer)
8-K - ACELYRIN, Inc. (0001962918) (Filer)
8-K/A - ACELYRIN, Inc. (0001962918) (Filer)
10-Q - ACELYRIN, Inc. (0001962918) (Filer)
DEFA14A - ACELYRIN, Inc. (0001962918) (Filer)
8-K - ACELYRIN, Inc. (0001962918) (Filer)
ARS - ACELYRIN, Inc. (0001962918) (Filer)
DEFA14A - ACELYRIN, Inc. (0001962918) (Filer)
DEF 14A - ACELYRIN, Inc. (0001962918) (Filer)
Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint of HiSCR75 at 12 weeks Company to prioritize development of lonigutamab; dose confirmation ongoing in Phase 2 trial with plans to initiate Phase 3 program in Q1 2025 Cash, cash equivalents, and short-term marketable securities at June 30, 2024 of $635.2 million; projected to extend cash runway to mid-2027 Company to hold webcast and conference call at 5:00pm ET today LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that the Phase 3 tria
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, August 13, 2024 at 5:00 p.m. ET to discuss its second quarter 2024 financial results and provide a corporate update. A live webcast of the conference call will be available on the Company's website under Events & Presentations. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRIN, INC.ACELYRIN, INC. (NASDAQ:SLRN) is a Los Angeles area-based late-stage clinical biopharma company –
LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, May 13, 2024 at 4:30 p.m. ET to discuss its first quarter 2024 financial results and provide a corporate update. A live webcast of the conference call will be available on the Company's website under Events & Presentations. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRIN, INC.ACELYRIN, INC. (NASDAQ:SLRN) is a Los Angeles area-based late-stage clinical biopharma company – wit
Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile Phase 2b/3 trial to be initiated in the second half of 2024 Conference call to review these data to be held at 8:30 a.m. ET today LOS ANGELES, March 20, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting t
Portfolio of programs continues to advance with data from both the global Phase 2b/3 trial for izokibep in PsA and proof-of-concept for lonigutamab as a subcutaneous treatment for thyroid eye disease expected in first quarter 2024 Additional PsA Phase 2 long-term data on clinical measures of disease resolution and quality of life to be presented at 2023 Annual Meeting of the American College of Rheumatology Cash, cash equivalents and short-term marketable securities totaled $788.4 million on September 30, 2023, providing runway through multiple key milestones across all three clinical programs Company to host conference call and webcast at 4:30 p.m. ET today LOS ANGELES, Nov.
LOS ANGELES, Oct. 31, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, November 7, 2023 at 4:30 p.m. ET to discuss its third quarter 2023 financial results and provide a corporate update. A live webcast of the conference call will be available on the Company's website under "Events" at the following link: https://www.acelyrin.com/events. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRINACELYRIN, INC. (NASDAQ:SLRN) is a Los Angeles area-based late
The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. HiSCR75 did meet statistical significance at week 16 in a Last Observation Carried Forward sensitivity analysis. HiSCR response rates of izokibep 160mg weekly (QW) were consistent with Part A open label results, demonstrating early onset of HiSCR100 at week 4, increasing through week 12 to 38% of patients in the Independently Conducted Pre-Planned Interim Analysis. Response was dose ordered, and safety was consistent with prior izokibep experience and not dose-limiting. Izokibep appears to be demonstrating consistent early and high orders of response
LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, August 14, 2023 at 4:30 p.m. ET to discuss its second quarter 2023 financial results and provide a corporate update. A live webcast of the conference call will be available on the Company's website under "Events" or at https://www.acelyrin.com/events. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRINACELYRIN, INC. is a Los Angeles area-based late-stage clinical biopharma compan
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Ava
Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company's Senior Leadership Team.
LOS ANGELES, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Lynn Tetrault to its board of directors. "I am pleased to welcome Lynn to our board of directors as we close our first year as a publicly traded company. Lynn is a highly accomplished biopharma executive and her extensive expertise spanning global human capital strategy, talent management, business operations, and corporate affairs adds a valuable dimension to support our evolving company," said Shao-Lee Lin, MD, PhD, Founder and CEO of ACELYRIN
Expands capacity for multi-asset manufacturing with highly accomplished supply chain, manufacturing and quality control leader bringing more than 25 years of biopharmaceutical experience across R&D, clinical and commercial supply management Joins at a pivotal time as ACELYRIN advances a robust portfolio of programs through late-stage clinical trials LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Patricia Turney as Chief Technical Operations Officer. Reporting to Founder and CEO Shao-Lee Lin
Veteran drug developer and prior CMO from Novartis AG gene therapies brings decades of clinical experience including long tenure as Global Lead for secukinumab, which he advanced from early development through to approvals across multiple indications including Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis and Hidradenitis Suppurativa Strong complement to ACELYRIN's current team and robust portfolio with multiple upcoming milestones that include Phase 2b/3 top-line data for izokibep in PsA and proof-of-concept for lonigutamab in thyroid eye disease, each expected before end of Q1 2024 LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clini
Accomplished global leader brings 20 years of immunology sales and marketing expertise. ACEYLRIN currently has a robust portfolio including late-stage clinical trials underway supporting multiple potential commercial launches in coming years. LOS ANGELES, July 18, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Ken Lock as Chief Commercial Officer, effectively immediately. Mr. Lock will report to Founder and Chief Executive Officer Shao-Lee Lin, MD, PhD and will serve on the Company's Senior Leadership Team.
Shares of Arhaus, Inc. (NASDAQ:ARHS) fell sharply during Monday's session. Jefferies analyst Jonathan Matuszewski downgraded Arhaus from Buy to Hold and lowered the price target from $22 to $16. Arhaus shares dipped 7.9% to $14.55 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Morphic Holding, Inc. (NASDAQ:MORF) shares jumped 75% to $55.72 after Eli Lilly agreed to buy the company for $57 per share in cash. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) climbed 71% to $6.97 after jumping around 50% on Friday. SRIVARU Holding Limited (NASDAQ:SVMH) shares climbed 61.3% to $0.2549 after the company announced the deployment of advanced
Wells Fargo analyst Derek Archila upgrades Acelyrin (NASDAQ:SLRN) from Equal-Weight to Overweight and maintains the price target from $13 to $13.
HC Wainwright & Co. analyst Emily Bodnar maintains Acelyrin (NASDAQ:SLRN) with a Buy and raises the price target from $16 to $18.
HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $16 price target.
HC Wainwright & Co. analyst Emily Bodnar maintains Acelyrin (NASDAQ:SLRN) with a Buy and lowers the price target from $28 to $18.
HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $28 price target.
Acelyrin (NASDAQ:SLRN) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.99) by 24.24 percent.
Wells Fargo analyst Derek Archila maintains Acelyrin (NASDAQ:SLRN) with a Equal-Weight and raises the price target from $11 to $13.